The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
A study by the University of California, San Diego, suggests semaglutide, a drug for weight loss and diabetes, may slow biological aging. Participants taking semaglutide showed a 9% reduction in aging rate and improved health markers compared to a placebo group.
A new analysis shows semaglutide (Ozempic/Wegovy) slows kidney disease progression in type 2 diabetes patients, improving kidney function and survival rates, even with a history of cardiovascular events. The drug mimics GLP-1 hormones and is also popular for weight loss.
Alkem Laboratories launched semaglutide in single-shot pre-filled syringes in India, making diabetes and obesity treatment more accessible and affordable. The company is the first in India to offer this format, intensifying competition in the growing drug market.
A UK study suggests Semaglutide may benefit patients unresponsive to bariatric surgery. Separately, oats are highlighted for their role in managing blood sugar for diabetics due to soluble fiber. Additionally, experts warn that processed foods, refined carbs, and high sodium/saturated fat diets can exacerbate stress hormone (cortisol) levels.
Scientists found that semaglutide and colchicine protect heart tissue from inflammation and electrical signaling disturbances that can cause arrhythmias. Semaglutide notably reduces scar tissue in the atria and maintains normal electrical impulse transmission.
Prices for generic semaglutide, a weight-loss drug, may drop by over 50% in 6-8 months due to new market entrants and reduced API costs, potentially reaching ₹500/month.
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
Dr Reddy's Laboratories has become the first company to receive Health Canada approval for generic semaglutide injection, covering 2 mg/pen and 4 mg/pen dosages. The approval, granted ahead of the regulatory review target date, marks a significant milestone in the company's GLP-1 journey and aims to expand access to affordable diabetes treatments for Canadian patients, where approximately 3.9 million people (9.7% of the population) live with diagnosed diabetes.
Dr Reddy's Laboratories has received notice of compliance from Health Canada for its generic semaglutide injection, becoming the first company to receive market authorization for this diabetes treatment in Canada. The approval covers 2 mg/pen and 4 mg/pen dosages. The company is preparing to launch the medication to provide Canadian patients with access to this therapy.
